{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:56:46Z","timestamp":1793332606887,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"crossref","award":["LHGJ20230054"],"award-info":[{"award-number":["LHGJ20230054"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"crossref","award":["SBGJ202102035"],"award-info":[{"award-number":["SBGJ202102035"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Henan Province Science and Technology Research and Development Plan Joint Fund Project","award":["225200810068"],"award-info":[{"award-number":["225200810068"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07415-6","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:00:08Z","timestamp":1751367608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Increased plasma GPNMB levels in patients with parkinson\u2019s disease and cognitive impairment"],"prefix":"10.1038","volume":"15","author":[{"given":"Xuelin","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghan","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"7415_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lfs.2019.03.057","volume":"226","author":"C Raza","year":"2019","unstructured":"Raza, C., Anjum, R. & Shakeel, N. U. A. Parkinson\u2019s disease: mechanisms, translational models and management strategies. Life Sci. 226, 77\u201390 (2019).","journal-title":"Life Sci."},{"key":"7415_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter, D. T. & Jenner, P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med. 62, 132\u2013144 (2013).","journal-title":"Free Radic. Biol. Med."},{"issue":"Suppl 1","key":"7415_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir, S. The clinical symptoms of parkinson\u2019s disease. J. Neurochem. 139 (Suppl 1), 318\u2013324 (2016).","journal-title":"J. Neurochem."},{"key":"7415_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.parkreldis.2014.12.011","volume":"21","author":"LP Oosterveld","year":"2015","unstructured":"Oosterveld, L. P. et al. Prognostic factors for early mortality in parkinson\u2019s disease. Parkinsonism Relat. Disord. 21, 226\u2013230 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"7415_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland, D. et al. Parkinson disease-associated cognitive impairment. Nat. Reviews Disease Primers. 7, 47 (2021).","journal-title":"Nat. Reviews Disease Primers"},{"key":"7415_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11011-021-00689-5","volume":"36","author":"V Zaman","year":"2021","unstructured":"Zaman, V. et al. Cellular and molecular pathophysiology in the progression of parkinson\u2019s disease. Metab. Brain Dis. 36, 815\u2013827 (2021).","journal-title":"Metab. Brain Dis."},{"key":"7415_CR7","doi-asserted-by":"publisher","first-page":"e12093","DOI":"10.1371\/journal.pone.0012093","volume":"5","author":"AA Rose","year":"2010","unstructured":"Rose, A. A. et al. ADAM10 releases a soluble form of the gpnmb\/osteoactivin extracellular domain with angiogenic properties. PloS One. 5, e12093 (2010).","journal-title":"PloS One"},{"key":"7415_CR8","first-page":"839","volume":"6","author":"G Maric","year":"2013","unstructured":"Maric, G., Rose, A. A., Annis, M. G. & Siegel, P. M. Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. OncoTargets Therapy. 6, 839\u2013852 (2013).","journal-title":"OncoTargets Therapy"},{"key":"7415_CR9","doi-asserted-by":"publisher","first-page":"eabk0637","DOI":"10.1126\/science.abk0637","volume":"377","author":"ME Diaz-Ortiz","year":"2022","unstructured":"Diaz-Ortiz, M. E. et al. GPNMB confers risk for parkinson\u2019s disease through interaction with \u03b1-synuclein. Sci. (New York N Y). 377, eabk0637 (2022).","journal-title":"Sci. (New York N Y)"},{"key":"7415_CR10","doi-asserted-by":"publisher","first-page":"106001","DOI":"10.1016\/j.parkreldis.2024.106001","volume":"120","author":"K Li","year":"2024","unstructured":"Li, K. et al. The association between plasma GPNMB and parkinson\u2019s disease and multiple system atrophy. Parkinsonism Relat. Disord. 120, 106001 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"7415_CR11","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamaneurol.2021.1312","volume":"78","author":"T Mitchell","year":"2021","unstructured":"Mitchell, T. et al. Emerging neuroimaging biomarkers across disease stage in Parkinson disease: A review. JAMA Neurol. 78, 1262\u20131272 (2021).","journal-title":"JAMA Neurol."},{"key":"7415_CR12","doi-asserted-by":"publisher","first-page":"e01808","DOI":"10.1002\/brb3.1808","volume":"10","author":"CH Park","year":"2020","unstructured":"Park, C. H., Lee, P. H., Lee, S. K., Chung, S. J. & Shin, N. Y. The diagnostic potential of multimodal neuroimaging measures in parkinson\u2019s disease and atypical parkinsonism. Brain Behav. 10, e01808 (2020).","journal-title":"Brain Behav."},{"key":"7415_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41582-022-00618-9","volume":"18","author":"JY Lee","year":"2022","unstructured":"Lee, J. Y. et al. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nat. Reviews Neurol. 18, 203\u2013220 (2022).","journal-title":"Nat. Reviews Neurol."},{"key":"7415_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.parkreldis.2022.10.007","volume":"104","author":"D Yoo","year":"2022","unstructured":"Yoo, D. et al. Diagnostic value of \u03b1-synuclein seeding amplification assays in \u03b1-synucleinopathies: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 104, 99\u2013109 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"7415_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M. & Soto, C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat. Protoc. 18, 1179\u20131196 (2023).","journal-title":"Nat. Protoc."},{"key":"7415_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.74.1.56","volume":"74","author":"DE Riley","year":"2003","unstructured":"Riley, D. E. & Chelimsky, T. C. Autonomic nervous system testing May not distinguish multiple system atrophy from parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry. 74, 56\u201360 (2003).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"7415_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/mds.1062","volume":"16","author":"B Holmberg","year":"2001","unstructured":"Holmberg, B., Kallio, M., Johnels, B. & Elam, M. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of parkinsonian syndromes. Mov. Disorders: Official J. Mov. Disorder Soc. 16, 217\u2013225 (2001).","journal-title":"Mov. Disorders: Official J. Mov. Disorder Soc."},{"key":"7415_CR18","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons, C. H. et al. Skin biopsy detection of phosphorylated \u03b1-Synuclein in patients with synucleinopathies. Jama 331, 1298\u20131306 (2024).","journal-title":"Jama"},{"key":"7415_CR19","doi-asserted-by":"crossref","unstructured":"Miglis, M. G. et al. Cutaneous \u03b1-synuclein is correlated with autonomic impairment in isolated rapid eye movement sleep behavior disorder. Sleep 44, 859 (2021).","DOI":"10.1093\/sleep\/zsab172"},{"key":"7415_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00401-023-02557-1","volume":"145","author":"S Dutta","year":"2023","unstructured":"Dutta, S., Hornung, S., Taha, H. B. & Bitan, G. Biomarkers for parkinsonian disorders in CNS-originating evs: promise and challenges. Acta Neuropathol. 145, 515\u2013540 (2023).","journal-title":"Acta Neuropathol."},{"key":"7415_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s00415-023-12093-3","volume":"271","author":"HB Taha","year":"2024","unstructured":"Taha, H. B. & Bogoniewski, A. Analysis of biomarkers in speculative CNS-enriched extracellular vesicles for parkinsonian disorders: a comprehensive systematic review and diagnostic meta-analysis. J. Neurol. 271, 1680\u20131706 (2024).","journal-title":"J. Neurol."},{"key":"7415_CR22","doi-asserted-by":"publisher","first-page":"e85595","DOI":"10.1371\/journal.pone.0085595","volume":"9","author":"I Rektorova","year":"2014","unstructured":"Rektorova, I. et al. Grey matter changes in cognitively impaired parkinson\u2019s disease patients. PloS One. 9, e85595 (2014).","journal-title":"PloS One"},{"key":"7415_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for parkinson\u2019s disease. Mov. Disorders: Official J. Mov. Disorder Soc. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disorders: Official J. Mov. Disorder Soc."},{"key":"7415_CR24","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of Levodopa dose equivalency reporting in parkinson\u2019s disease. Mov. Disorders: Official J. Mov. Disorder Soc. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disorders: Official J. Mov. Disorder Soc."},{"key":"7415_CR25","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement disorder Society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disorders: Official J. Mov. Disorder Soc. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disorders: Official J. Mov. Disorder Soc."},{"key":"7415_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","volume":"14","author":"W Maier","year":"1988","unstructured":"Maier, W., Buller, R., Philipp, M. & Heuser, I. The Hamilton anxiety scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J. Affect. Disord. 14, 61\u201368 (1988).","journal-title":"J. Affect. Disord."},{"key":"7415_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/1099-1166(200007)15:7<644::AID-GPS167>3.0.CO;2-L","volume":"15","author":"AF Leentjens","year":"2000","unstructured":"Leentjens, A. F., Verhey, F. R., Lousberg, R., Spitsbergen, H. & Wilmink, F. W. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in parkinson\u2019s disease. Int. J. Geriatr. Psychiatry. 15, 644\u2013649 (2000).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"7415_CR28","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.sleep.2014.03.020","volume":"15","author":"SS Shen","year":"2014","unstructured":"Shen, S. S. et al. Validation study of REM sleep behavior disorder questionnaire-Hong Kong (RBDQ-HK) in East China. Sleep Med. 15, 952\u2013958 (2014).","journal-title":"Sleep Med."},{"key":"7415_CR29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/mds.26276","volume":"30","author":"M Rossi","year":"2015","unstructured":"Rossi, M. et al. Olfactory dysfunction evaluation is not affected by comorbid depression in parkinson\u2019s disease. Mov. Disorders: Official J. Mov. Disorder Soc. 30, 1275\u20131279 (2015).","journal-title":"Mov. Disorders: Official J. Mov. Disorder Soc."},{"issue":"Suppl 1","key":"7415_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000058047","volume":"46","author":"KR Chaudhuri","year":"2001","unstructured":"Chaudhuri, K. R., Pal, S., Bridgman, K. & Trenkwalder, C. Achieving 24-hour control of parkinson\u2019s disease symptoms: use of objective measures to improve nocturnal disability. Eur. Neurol. 46 (Suppl 1), 3\u201310 (2001).","journal-title":"Eur. Neurol."},{"key":"7415_CR31","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1212\/WNL.57.8.1392","volume":"57","author":"WG Ondo","year":"2001","unstructured":"Ondo, W. G. et al. Daytime sleepiness and other sleep disorders in parkinson\u2019s disease. Neurology 57, 1392\u20131396 (2001).","journal-title":"Neurology"},{"key":"7415_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.parkreldis.2008.11.013","volume":"15","author":"CL Dotchin","year":"2009","unstructured":"Dotchin, C. L., Jusabani, A. & Walker, R. W. Non-motor symptoms in a prevalent population with parkinson\u2019s disease in Tanzania. Parkinsonism Relat. Disord. 15, 457\u2013460 (2009).","journal-title":"Parkinsonism Relat. Disord."},{"key":"7415_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0891988711422528","volume":"24","author":"J Lu","year":"2011","unstructured":"Lu, J. et al. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. J. Geriatr. Psychiatr. Neurol. 24, 184\u2013190 (2011).","journal-title":"J. Geriatr. Psychiatr. Neurol."},{"key":"7415_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s12888-021-03495-6","volume":"21","author":"X Jia","year":"2021","unstructured":"Jia, X. et al. A comparison of the Mini-Mental state examination (MMSE) with the Montreal cognitive assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry. 21, 485 (2021).","journal-title":"BMC Psychiatry"},{"key":"7415_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/jmri.10064","volume":"15","author":"DT Chard","year":"2002","unstructured":"Chard, D. T., Parker, G. J., Griffin, C. M., Thompson, A. J. & Miller, D. H. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J. Magn. Reson. Imaging: JMRI. 15, 259\u2013267 (2002).","journal-title":"J. Magn. Reson. Imaging: JMRI"},{"key":"7415_CR36","doi-asserted-by":"publisher","first-page":"621508","DOI":"10.3389\/fnagi.2021.621508","volume":"13","author":"W Sun","year":"2021","unstructured":"Sun, W. et al. Increased plasma Heme Oxygenase-1 levels in patients with Early-Stage parkinson\u2019s disease. Front. Aging Neurosci. 13, 621508 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"7415_CR37","doi-asserted-by":"publisher","first-page":"39818","DOI":"10.1038\/srep39818","volume":"7","author":"A Shiino","year":"2017","unstructured":"Shiino, A. et al. Sex-related difference in human white matter volumes studied: inspection of the corpus callosum and other white matter by VBM. Sci. Rep. 7, 39818 (2017).","journal-title":"Sci. Rep."},{"key":"7415_CR38","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1038\/s41467-021-26280-1","volume":"12","author":"CS Storm","year":"2021","unstructured":"Storm, C. S. et al. Finding genetically-supported drug targets for parkinson\u2019s disease using Mendelian randomization of the druggable genome. Nat. Commun. 12, 7342 (2021).","journal-title":"Nat. Commun."},{"key":"7415_CR39","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1038\/s41467-021-27387-1","volume":"12","author":"G Png","year":"2021","unstructured":"Png, G. et al. Mapping the serum proteome to neurological diseases using whole genome sequencing. Nat. Commun. 12, 7042 (2021).","journal-title":"Nat. Commun."},{"key":"7415_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41531-023-00591-0","volume":"9","author":"XJ Gu","year":"2023","unstructured":"Gu, X. J. et al. Expanding causal genes for parkinson\u2019s disease via multi-omics analysis. NPJ Parkinson\u2019s Dis.. 9, 146 (2023).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"7415_CR41","doi-asserted-by":"crossref","unstructured":"Pajares, M., Manda, A. I. R., Bosc\u00e1, G. & Cuadrado, A. L. Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells 9, 563 (2020).","DOI":"10.3390\/cells9071687"},{"key":"7415_CR42","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/brain\/awab446","volume":"145","author":"S Smaji\u0107","year":"2022","unstructured":"Smaji\u0107, S. et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain: J. Neurol. 145, 964\u2013978 (2022).","journal-title":"Brain: J. Neurol."},{"key":"7415_CR43","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1038\/s41467-023-39060-w","volume":"14","author":"AM Schonhoff","year":"2023","unstructured":"Schonhoff, A. M. et al. Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease. Nat. Commun. 14, 3754 (2023).","journal-title":"Nat. Commun."},{"key":"7415_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2018.08.013","volume":"120","author":"EB Moloney","year":"2018","unstructured":"Moloney, E. B., Moskites, A., Ferrari, E. J., Isacson, O. & Hallett, P. J. The glycoprotein GPNMB is selectively elevated in the substantia Nigra of parkinson\u2019s disease patients and increases after lysosomal stress. Neurobiol. Dis. 120, 1\u201311 (2018).","journal-title":"Neurobiol. Dis."},{"key":"7415_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12031-014-0280-0","volume":"54","author":"F Shi","year":"2014","unstructured":"Shi, F. et al. Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression. J. Mol. Neuroscience: MN. 54, 234\u2013242 (2014).","journal-title":"J. Mol. Neuroscience: MN"},{"key":"7415_CR46","doi-asserted-by":"publisher","first-page":"889257","DOI":"10.3389\/fnagi.2022.889257","volume":"14","author":"CZ Liu","year":"2022","unstructured":"Liu, C. Z. et al. Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with parkinson\u2019s disease. Front. Aging Neurosci. 14, 889257 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"7415_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12974-018-1100-1","volume":"15","author":"ML Neal","year":"2018","unstructured":"Neal, M. L., Boyle, A. M., Budge, K. M., Safadi, F. F. & Richardson, J. R. The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. J. Neuroinflamm. 15, 73 (2018).","journal-title":"J. Neuroinflamm."},{"key":"7415_CR48","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1007\/s12035-020-01921-6","volume":"57","author":"KM Budge","year":"2020","unstructured":"Budge, K. M., Neal, M. L., Richardson, J. R. & Safadi, F. F. Transgenic overexpression of GPNMB protects against MPTP-Induced neurodegeneration. Mol. Neurobiol. 57, 2920\u20132933 (2020).","journal-title":"Mol. Neurobiol."},{"key":"7415_CR49","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.4049\/jimmunol.178.10.6557","volume":"178","author":"VM Ripoll","year":"2007","unstructured":"Ripoll, V. M., Irvine, K. M., Ravasi, T., Sweet, M. J. & Hume, D. A. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of Proinflammatory responses. J. Immunol. (Baltimore Md. : 1950). 178, 6557\u20136566 (2007).","journal-title":"J. Immunol. (Baltimore Md. : 1950)"},{"key":"7415_CR50","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3174\/ajnr.A4055","volume":"35","author":"E Mak","year":"2014","unstructured":"Mak, E., Bergsland, N., Dwyer, M. G., Zivadinov, R. & Kandiah, N. Subcortical atrophy is associated with cognitive impairment in mild Parkinson disease: a combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis. AJNR Am. J. Neuroradiol. 35, 2257\u20132264 (2014).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"7415_CR51","doi-asserted-by":"crossref","unstructured":"Murthy, M. N. et al. Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson\u2019s disease on chromosome 7p15.3. Neurogenetics 18, 121\u2013133 (2017).","DOI":"10.1007\/s10048-017-0514-8"},{"key":"7415_CR52","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.clinph.2019.04.314","volume":"130","author":"D H\u00fcnerli","year":"2019","unstructured":"H\u00fcnerli, D. et al. Mild cognitive impairment in parkinson\u2019s disease is associated with decreased P300 amplitude and reduced putamen volume. Clin. Neurophysiol. Off. J. Int. Feder. Clin. Neurophysiol. 130, 1208\u20131217 (2019).","journal-title":"Clin. Neurophysiol. Off. J. Int. Feder. Clin. Neurophysiol."},{"key":"7415_CR53","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neurobiolaging.2022.10.001","volume":"121","author":"D H\u00fcnerli-G\u00fcnd\u00fcz","year":"2023","unstructured":"H\u00fcnerli-G\u00fcnd\u00fcz, D. et al. Reduced power and phase-locking values were accompanied by thalamus, putamen, and hippocampus atrophy in parkinson\u2019s disease with mild cognitive impairment: an event-related Oscillation study. Neurobiol. Aging. 121, 88\u2013106 (2023).","journal-title":"Neurobiol. Aging"},{"key":"7415_CR54","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/01616412.2023.2258038","volume":"45","author":"E Kobak Tur","year":"2023","unstructured":"Kobak Tur, E. & Ari, B. C. Mild cognitive impairment in patients with parkinson\u00b4s disease and the analysis of associated factors. Neurol. Res. 45, 1161\u20131168 (2023).","journal-title":"Neurol. Res."},{"key":"7415_CR55","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12974-023-02965-w","volume":"20","author":"DA Gillett","year":"2023","unstructured":"Gillett, D. A., Wallings, R. L., Huarte, U., Tansey, M. G. & O. & Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease. J. Neuroinflamm. 20, 286 (2023).","journal-title":"J. Neuroinflamm."},{"key":"7415_CR56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40659-021-00332-8","volume":"54","author":"K Lv","year":"2021","unstructured":"Lv, K. et al. Long non-coding RNA MALAT1 regulates cell proliferation and apoptosis via miR-135b-5p\/GPNMB axis in parkinson\u2019s disease cell model. Biol. Res. 54, 10 (2021).","journal-title":"Biol. Res."},{"key":"7415_CR57","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s43587-021-00151-2","volume":"1","author":"M Suda","year":"2021","unstructured":"Suda, M. et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat. Aging. 1, 1117\u20131126 (2021).","journal-title":"Nat. Aging"},{"key":"7415_CR58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40478-018-0612-3","volume":"6","author":"M H\u00fcttenrauch","year":"2018","unstructured":"H\u00fcttenrauch, M. et al. Glycoprotein NMB: a novel alzheimer\u2019s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol. Commun. 6, 108 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"7415_CR59","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/jnr.23999","volume":"95","author":"Y Nagahara","year":"2017","unstructured":"Nagahara, Y. et al. GPNMB ameliorates mutant TDP-43-induced motor neuron cell death. J. Neurosci. Res. 95, 1647\u20131665 (2017).","journal-title":"J. Neurosci. Res."},{"key":"7415_CR60","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/srep00573","volume":"2","author":"H Tanaka","year":"2012","unstructured":"Tanaka, H. et al. The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci. Rep. 2, 573 (2012).","journal-title":"Sci. Rep."},{"key":"7415_CR61","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/2211-5463.12078","volume":"6","author":"G Kramer","year":"2016","unstructured":"Kramer, G. et al. Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 gaucher disease patients and mouse models. FEBS Open. Bio. 6, 902\u2013913 (2016).","journal-title":"FEBS Open. Bio"},{"key":"7415_CR62","doi-asserted-by":"publisher","first-page":"e0147208","DOI":"10.1371\/journal.pone.0147208","volume":"11","author":"AR Marques","year":"2016","unstructured":"Marques, A. R. et al. Gpnmb is a potential marker for the visceral pathology in Niemann-Pick type C disease. PloS One. 11, e0147208 (2016).","journal-title":"PloS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07415-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07415-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07415-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:02:57Z","timestamp":1759485777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07415-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7415"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07415-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies involving human participants were reviewed and approved by the Medical Ethics Committee of Henan Provincial People\u2019s Hospital(2024\u201246). All experiments were carried out in accordance with relevant guidelines and regulations. The patients\/participants provided their written informed consent to participate in this study.The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"20684"}}